Double chins banished with 'fatburner injections'?

Conclusion This was a well-conducted, randomised controlled trial that examined the effectiveness and safety of an injected treatment (ATX-101) for excess fat under the chin compared with an inactive placebo injection. This is described to be one of the first trials of a non-surgical treatment for reducing fat under the chin. The study benefits from its reasonably large sample size, inclusion of doctor and patient measures of treatment effect, and its double blind design. The study found significant improvements with ATX-101 according to both clinician and patient-ratings. However, there are some cautions to bear in mind: Side effects, though for the most part mild and transient, were very common in the treatment group. Injection-related pain in particular was rated to be moderate to severe by between one-quarter and one-third of people receiving treatment. Also 13% withdrew from further treatment sessions due to side effects. Therefore, though a non-invasive treatment, some people did not find the side effects tolerable. Also related to the double blind design, the ATX-101 was associated with more side effects than placebo, so it is possible that some doctors or patients may have guessed that they were receiving an active treatment. The study has looked at the effects of up to four treatments given over a 12-week period. It would be useful to know the effects in the longer term, and whether they were maintained or whether further treatments were needed. ...
Source: NHS News Feed - Category: Consumer Health News Tags: Obesity Medication Source Type: news